Centessa Pharmaceuticals plc - Ordinary Shares, nominal value GBP 0.002 per share (CNTA)
CUSIP: 152309100
Q2 2025 13F Holders as of 30 Jun 2025
- Type / Class
- Equity / Ordinary Shares, nominal value GBP 0.002 per share
- Shares outstanding
- 154,150,943
- Total 13F shares
- 123,569,478
- Share change
- -1,378,818
- Total reported value
- $1,623,678,828
- Put/Call ratio
- 23%
- Price per share
- $13.14
- Number of holders
- 117
- Value change
- -$30,690,539
- Number of buys
- 62
- Number of sells
- 67
Quarterly Holders Quick Answers
What is CUSIP 152309100?
CUSIP 152309100 identifies CNTA - Centessa Pharmaceuticals plc - Ordinary Shares, nominal value GBP 0.002 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 152309100:
Top shareholders of CNTA - Centessa Pharmaceuticals plc - Ordinary Shares, nominal value GBP 0.002 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd |
13F
3/4/5
|
Company · 10%+ Owner |
13%
|
19,963,157
|
$287,070,198 | — | 31 Mar 2025 | |
| Index Venture Life Associates VI Ltd |
13F
|
Company |
6.5%
|
9,961,789
|
$143,250,526 | — | 31 Mar 2025 | |
| GENERAL ATLANTIC, L.P. |
13F
|
Individual |
6.3%
|
9,681,818
|
$139,224,543 | — | 31 Mar 2025 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
|
Company |
4.5%
|
6,954,000
|
$99,998,520 | — | 31 Mar 2025 | |
| JANUS HENDERSON GROUP PLC |
13F
|
Company |
3.8%
|
5,922,486
|
$86,388,113 | — | 31 Mar 2025 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
3.5%
|
5,342,344
|
$76,823,000 | — | 31 Mar 2025 | |
| First Light Asset Management, LLC |
13F
|
Company |
3.2%
|
4,874,124
|
$70,089,903 | — | 31 Mar 2025 | |
| FARALLON CAPITAL MANAGEMENT LLC |
13F
|
Company |
2.8%
|
4,334,318
|
$62,327,493 | — | 31 Mar 2025 | |
| Avoro Capital Advisors LLC |
13F
|
Company |
2.6%
|
4,050,000
|
$58,239,000 | — | 31 Mar 2025 | |
| FMR LLC |
13F
|
Company |
2.5%
|
3,826,194
|
$55,020,670 | — | 31 Mar 2025 | |
| PERCEPTIVE ADVISORS LLC |
13F
|
Company |
2%
|
3,040,395
|
$43,720,880 | — | 31 Mar 2025 | |
| Siren, L.L.C. |
13F
|
Individual |
1.9%
|
2,960,029
|
$42,565,217 | — | 31 Mar 2025 | |
| MORGAN STANLEY |
13F
|
Company |
1.9%
|
2,937,467
|
$42,240,777 | — | 31 Mar 2025 | |
| TCG Crossover Management, LLC |
13F
|
Company |
1.9%
|
2,890,816
|
$41,569,934 | — | 31 Mar 2025 | |
| FRANKLIN RESOURCES INC |
13F
|
Company |
1.6%
|
2,541,999
|
$36,553,943 | — | 31 Mar 2025 | |
| Commodore Capital LP |
13F
|
Company |
1.5%
|
2,367,578
|
$34,045,772 | — | 31 Mar 2025 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
1.5%
|
2,286,433
|
$32,878,907 | — | 31 Mar 2025 | |
| Cormorant Asset Management, LP |
13F
|
Company |
1.5%
|
2,261,600
|
$32,521,808 | — | 31 Mar 2025 | |
| Holocene Advisors, LP |
13F
|
Company |
1.5%
|
2,255,679
|
$32,436,664 | — | 31 Mar 2025 | |
| T. Rowe Price Investment Management, Inc. |
13F
|
Company |
1.1%
|
1,753,248
|
$25,212,000 | — | 31 Mar 2025 | |
| Affinity Asset Advisors, LLC |
13F
|
Company |
1%
|
1,546,662
|
$22,241,000 | — | 31 Mar 2025 | |
| Octagon Capital Advisors LP |
13F
|
Company |
0.92%
|
1,425,000
|
$20,491,500 | — | 31 Mar 2025 | |
| Foresite Capital Management VI LLC |
13F
|
Company |
0.81%
|
1,253,379
|
$18,023,590 | — | 31 Mar 2025 | |
| BAKER BROS. ADVISORS LP |
13F
|
Company |
0.8%
|
1,227,178
|
$17,646,820 | — | 31 Mar 2025 | |
| DRIEHAUS CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.71%
|
1,095,533
|
$15,753,765 | — | 31 Mar 2025 | |
| AMERICAN CENTURY COMPANIES INC |
13F
|
Company |
0.71%
|
1,092,754
|
$15,713,814 | — | 31 Mar 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.58%
|
899,505
|
$12,934,882 | — | 31 Mar 2025 | |
| 5AM Venture Management, LLC |
13F
|
Company |
0.54%
|
830,945
|
$11,948,989 | — | 31 Mar 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.46%
|
706,331
|
$10,157,040 | — | 31 Mar 2025 | |
| Tanager Wealth Management LLP |
13F
|
Company |
0.45%
|
696,096
|
$10,009,860 | — | 31 Mar 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.4%
|
609,188
|
$8,760,123 | — | 31 Mar 2025 | |
| STEMPOINT CAPITAL LP |
13F
|
Company |
0.38%
|
593,335
|
$8,532,157 | — | 31 Mar 2025 | |
| TD ASSET MANAGEMENT INC |
13F
|
Company |
0.38%
|
588,122
|
$8,457,194 | — | 31 Mar 2025 | |
| PFM Health Sciences, LP |
13F
|
Company |
0.37%
|
570,546
|
$8,204,451 | — | 31 Mar 2025 | |
| Nantahala Capital Management, LLC |
13F
|
Company |
0.36%
|
554,803
|
$7,978,067 | — | 31 Mar 2025 | |
| David J. Grainger |
3/4/5
|
Chief Innovation Officer |
—
class O/S missing
|
990,290
|
$7,882,708 | — | 31 Dec 2023 | |
| Avidity Partners Management LP |
13F
|
Company |
0.34%
|
529,000
|
$7,607,020 | — | 31 Mar 2025 | |
| ARMISTICE CAPITAL, LLC |
13F
|
Company |
0.3%
|
468,000
|
$6,729,840 | — | 31 Mar 2025 | |
| Saturn V Capital Management LP |
13F
|
Company |
0.29%
|
448,692
|
$6,452,191 | — | 31 Mar 2025 | |
| LORD, ABBETT & CO. LLC |
13F
|
Company |
0.29%
|
446,196
|
$6,416,000 | — | 31 Mar 2025 | |
| Ensign Peak Advisors, Inc |
13F
|
Company |
0.28%
|
438,133
|
$6,300,353 | — | 31 Mar 2025 | |
| Antoine Yver |
3/4/5
|
EVP & Chairman of Development |
—
class O/S missing
|
783,066
|
$6,233,205 | — | 01 Jun 2023 | |
| Cutter Capital Management, LP |
13F
|
Company |
0.27%
|
418,127
|
$6,012,666 | — | 31 Mar 2025 | |
| Arjun Goyal |
3/4/5
|
Director |
—
mixed-class rows
|
502,585
mixed-class rows
|
$5,886,902 | — | 20 Jun 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.26%
|
401,764
|
$5,777,366 | — | 31 Mar 2025 | |
| Woodline Partners LP |
13F
|
Company |
0.26%
|
400,278
|
$5,755,998 | — | 31 Mar 2025 | |
| BlackRock, Inc. |
13F
|
Company |
0.26%
|
399,966
|
$5,751,511 | — | 31 Mar 2025 | |
| Allostery Investments LP |
13F
|
Company |
0.25%
|
382,524
|
$5,500,695 | — | 31 Mar 2025 | |
| Blue Owl Capital Holdings LP |
13F
|
Company |
0.2%
|
315,000
|
$4,529,700 | — | 31 Mar 2025 | |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE |
13F
|
Company |
0.2%
|
302,646
|
$4,352,049 | — | 31 Mar 2025 |
Institutional Holders of Centessa Pharmaceuticals plc - Ordinary Shares, nominal value GBP 0.002 per share (CNTA) as of Q2 2025
As of 30 Jun 2025,
Centessa Pharmaceuticals plc - Ordinary Shares, nominal value GBP 0.002 per share (CNTA) was held by
117 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
123,569,478 shares.
The largest 10 holders included
Medicxi Ventures Management (Jersey) Ltd, Index Venture Life Associates VI Ltd, GENERAL ATLANTIC, L.P., ADAGE CAPITAL PARTNERS GP, L.L.C., JANUS HENDERSON GROUP PLC, PRICE T ROWE ASSOCIATES INC /MD/, Avoro Capital Advisors LLC, FARALLON CAPITAL MANAGEMENT LLC, First Light Asset Management, LLC, and FMR LLC.
This page lists
117
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
130
Q2 2025 holders
117
Holder diff
-13
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 Value $ | Q2 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.